 | Up a level |
Mark, M; Rusakiewicz, S; Früh, M; Hayoz, S; Grosso, F; Pless, M; Zucali, P; Ceresoli, G L; Maconi, A; Schneider, M; Froesch, P; Tarussio, D; Benedetti, F; Dagher, J; Kandalaft, L; von Moos, R; Tissot-Renaud, S; Schmid, S; Metaxas, Y (2022). Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO open, 7(3), p. 100446. BMJ 10.1016/j.esmoop.2022.100446
Schirmer, J H; Aries, P M; Balzer, K; Berlit, P; Bley, T A; Buttgereit, F; Czihal, M; Dechant, C; Dejaco, C; Garske, U; Henes, J; Holle, J U; Holl-Ulrich, K; Lamprecht, P; Nölle, B; Moosig, F; Rech, J; Scheuermann, K; Schmalzing, M; Schmidt, W A; ... (2020). [S2k guidelines (executive summary): management of large-vessel vasculitis]. Zeitschrift für Rheumatologie, 79(9), pp. 937-942. Springer-Medizin-Verlag 10.1007/s00393-020-00894-0
Schirmer, J H; Aries, P M; Balzer, K; Berlit, P; Bley, T A; Buttgereit, F; Czihal, M; Dechant, C; Dejaco, C; Garske, U; Henes, J; Holle, J U; Holl-Ulrich, K; Lamprecht, P; Nölle, B; Moosig, F; Rech, J; Scheuermann, K; Schmalzing, M; Schmidt, W A; ... (2020). [S2k guidelines: management of large-vessel vasculitis]. Zeitschrift für Rheumatologie, 79(Suppl 3), pp. 67-95. Springer-Medizin-Verlag 10.1007/s00393-020-00893-1
Heiligenhaus, A; Minden, K; Tappeiner, Christoph; Baus, H; Bertram, B; Deuter, C; Foeldvari, I; Föll, D; Frosch, M; Ganser, G; Gaubitz, M; Günther, A; Heinz, C; Horneff, G; Huemer, C; Kopp, I; Lommatzsch, C; Lutz, T; Michels, H; Neß, T; ... (2019). Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Seminars in arthritis and rheumatism, 49(1), pp. 43-55. Elsevier 10.1016/j.semarthrit.2018.11.004
Schneider, M; Waschk, Maja Alice; Precht, Maria Christina; Nathues, Christina; Moissonnier, P; Aikawa, T; Schnötzinger, D; Schmidt, M; Garosi, D; Forterre, Franck (2017). Incidence of Abnormalities of the Second and Third Cervical Vertebral Junction in Dogs with Atlantoaxial Instability: A Multicentre Study. Veterinary and comparative orthopaedics and traumatology, 30(6), pp. 424-429. Schattauer 10.3415/VCOT-17-01-0004
Andreoli, L; Bertsias, G K; Agmon-Levin, N; Brown, S; Cervera, R; Costedoat-Chalumeau, N; Doria, A; Fischer-Betz, R; Forger, F; Moraes-Fontes, M F; Khamashta, M; King, J; Lojacono, A; Marchiori, F; Meroni, P L; Mosca, M; Motta, M; Ostensen, M; Pamfil, C; Raio, Luigi; ... (2017). EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Annals of the rheumatic diseases, 76(3), pp. 476-485. BMJ Publishing Group 10.1136/annrheumdis-2016-209770
Armando, M; Schneider, M; Pontillo, M; Vicari, S; Debbané, M; Schultze-Lutter, F; Eliez, S (2017). No age effect in the prevalence and clinical significance of ultra-high risk symptoms and criteria for psychosis in 22q11 deletion syndrome: Confirmation of the genetically driven risk for psychosis? PLoS ONE, 12(4), e0174797. Public Library of Science 10.1371/journal.pone.0174797
Schneider, M; Armando, M; Pontillo, M; Vicari, S; Debbané, M; Eliez, S; Schultze-Lutter, F (2016). Ultra high risk status and transition to psychosis in 22q11.2 deletion syndrome. World psychiatry, 15(3), pp. 259-265. Wiley 10.1002/wps.20347
Aringer, M; Burkhardt, H; Burmester, G R; Fischer-Betz, R; Fleck, M; Graninger, W; Hiepe, F; Jacobi, A M; Kötter, I; Lakomek, H J; Lorenz, H M; Manger, B; Schett, G; Schmidt, R E; Schneider, M; Schulze-Koops, H; Smolen, J S; Specker, C; Stoll, T; Strangfeld, A; ... (2012). Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. Lupus, 21(4), pp. 386-401. London: Sage 10.1177/0961203311426569
Krudewig, J; Baumann, U; Bernuth von, H; Borte, M; Burkhard-Meier, U; Dueckers, G; Foerster-Waldl, E; Franke, K; Habermehl, P; Hönig, M; Kern, W; Kösters, K; Kugel, K; Lehrnbecher, T; Liese, J; Marks, R; Müller, G A; Müller, R; Nadal, D; Peter, H-H; ... (2012). [Interdisciplinary AWMF guideline for the treatment of primary antibody deficiencies]. Klinische Pädiatrie, 224(6), pp. 404-15. Stuttgart: Thieme 10.1055/s-0032-1323837
Miese, FR; Ostendorf, B; Wittsack, HJ; Reichelt, DC; Mamisch, TC; Zilkens, C; Lanzman, RS; Schneider, M; Scherer, A (2010). Metacarpophalangeal joints in rheumatoid arthritis: delayed gadolinium-enhanced MR imaging of cartilage - a feasibility study. Radiology, 257(2), pp. 441-7. Oak Brook, Ill.: Radiological Society of North America RSNA 10.1148/radiol.10100459
Miese, FR; Ostendorf, B; Wittsack, HJ; Reichelt, DC; Kröpil, P; Lanzman, RS; Mamisch, TC; Zilkens, C; Jellus, V; Quentin, M; Schneider, M; Scherer, A (2010). Knorpelqualität an den Fingergelenken: delayed Gd(DTPA)²-enhanced MRI of the cartilage (dGEMRIC) bei 3T [Cartilage quality in finger joints: delayed Gd(DTPA)²-enhanced MRI of the cartilage (dGEMRIC) at 3T]. RöFo. Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 182(10), pp. 873-8. Stuttgart: Thieme 10.1055/s-0029-1245596
Schneider, M; Hirt, C; Casaulta, C; Barben, J; Spinas, R; Bühlmann, U; Spalinger, J; Schwizer, B; Chevalier-Porst, F; Gallati, S (2007). Large deletions in the CFTR gene: clinics and genetics in Swiss patients with CF. Clinical genetics, 72(1), pp. 30-8. Oxford: Wiley-Blackwell 10.1111/j.1399-0004.2007.00820.x
Laederach-Hofmann, K; Graf, C; Horber, F; Lippuner, K; Lederer, S; Michel, R; Schneider, M (1999). Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. International journal of eating disorders, 26(3), pp. 231-44. New York, N.Y.: John Wiley & Sons Inc. 10.1002/(SICI)1098-108X(199911)26:3<231::AID-EAT1>3.0.CO;2-6
Rothschild, S; Amrein, Michael; Riether, Carsten; Gautschi, O; Schuster, N; Li, Q; Savic, S; Schneider, M; Biaggi, C; Bubendorf, L; Brutsche, M; Zippelius, A; Zander, T; Betticher, D; Früh, M; Stahel, R; Cathomas, R; Rauch, Daniel; Pless, M; Ochsenbein, Adrian; ... (October 2017). CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09). Journal of thoracic oncology, 12(11S2), S1864-S1865. Elsevier
Armando, M; Schneider, M; Pontillo, M; Vicari, S; Debbané, M; Schultze-Lutter, F; Eliez, S (2016). Age matters in the prevalence and clinical significance of ultra-high-risk for psychosis symptoms and criteria in 22q11 Deletion Syndrome. Early intervention in psychiatry, 10(S1), p. 120. Blackwell Publishing Asia
Schneider, M; Armando, M; Pontillo, M; Vicari, S; Debbane, M; Schultze-Lutter, F; Eliez, S (2016). Ultra high-risk status and transition to psychosis in 22q11.2 deletion syndrome. Early intervention in psychiatry, 10(S1), p. 168. Blackwell Publishing Asia
Barrantes-Vidal, N; Schneider, M; Fonseca-Pedrero, E; Flückiger, Rahel (2016). Schizotypy in youths: Stress, cognition and relationships with transition to psychosis. Early intervention in psychiatry, 10(S1), p. 52. Wiley
